Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series

Ann Oncol. 2012 Mar;23(3):804-805. doi: 10.1093/annonc/mdr631. Epub 2012 Jan 31.

Authors

G Roubaud¹, M Kind², J-M Coindre³, R G Maki⁴, B Bui¹, A Italiano¹

Affiliations

¹ Departments of Medical Oncology.
² Departments of Radiology.
³ Departments of Pathology, Institut Bergonié, Bordeaux, France.
⁴ Department of Medicine and Pediatrics, Sarcoma Service, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: italiano@bergonie.org.

PMID: 22294526
DOI: 10.1093/annonc/mdr631

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzenesulfonates / therapeutic use*
Exons / genetics
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / genetics*
Gastrointestinal Stromal Tumors / drug therapy*
Gastrointestinal Stromal Tumors / genetics*
Humans
Mutation*
Niacinamide / analogs & derivatives
Phenylurea Compounds
Pyridines / therapeutic use*
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Sorafenib

Substances

Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Pyridines
Niacinamide
Sorafenib
Receptor, Platelet-Derived Growth Factor alpha